Humana Inc. (NYSE:HUM) Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 20.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,184 shares of the insurance provider’s stock after selling 836 shares during the quarter. OLD National Bancorp IN’s holdings in Humana were worth $1,458,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. acquired a new stake in Humana during the 4th quarter valued at approximately $25,000. Gradient Investments LLC grew its stake in Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A acquired a new stake in Humana during the 4th quarter valued at approximately $28,000. Nvwm LLC grew its stake in Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Operose Advisors LLC acquired a new stake in Humana during the 3rd quarter valued at approximately $56,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the purchase, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is owned by company insiders.

Humana Stock Down 0.9 %

Shares of Humana stock opened at $325.30 on Tuesday. The business’s fifty day moving average price is $330.09 and its two-hundred day moving average price is $399.70. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. The company has a market capitalization of $39.25 billion, a P/E ratio of 16.41, a PEG ratio of 1.92 and a beta of 0.45. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21.

Humana (NYSE:HUM) last announced its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The business had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm’s revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.62 EPS. As a group, research analysts forecast that Humana Inc. will post 16.06 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is currently 17.86%.

Analysts Set New Price Targets

Several brokerages have recently commented on HUM. Stephens decreased their target price on Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research report on Friday, January 26th. Jefferies Financial Group decreased their target price on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research report on Monday. Raymond James began coverage on Humana in a research report on Friday, March 22nd. They issued a “market perform” rating for the company. TD Cowen decreased their target price on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $391.00 target price on shares of Humana in a research report on Wednesday, April 10th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average price target of $454.63.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.